Trial Profile
A Prospective Comparative Study of Preference and Efficacy of Adalimumab and Infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 06 Sep 2017 New trial record
- 01 Aug 2017 Results published in the Medicine